Sandoz Sees Revolution In US Biosimilars Market
After A Slow Start, Five Years On The US Is Delivering On Its Potential
Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.
